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Abstract
Schizophrenia (SCZ) and bipolar disorder (BD) are severe mental disorders associated with cognitive impairment, which is
considered a major determinant of functional outcome. Despite this, the etiology of the cognitive impairment is poorly
understood, and no satisfactory cognitive treatments exist. Increasing evidence indicates that genetic risk for SCZ may
contribute to cognitive impairment, whereas the genetic relationship between BD and cognitive function remains unclear.
Here, we combined large genome-wide association study data on SCZ (n= 82,315), BD (n= 51,710), and general
intelligence (n= 269,867) to investigate overlap in common genetic variants using conditional false discovery rate
(condFDR) analysis. We observed substantial genetic enrichment in both SCZ and BD conditional on associations with
intelligence indicating polygenic overlap. Using condFDR analysis, we leveraged this enrichment to increase statistical
power and identified 75 distinct genomic loci associated with both SCZ and intelligence, and 12 loci associated with both
BD and intelligence at conjunctional FDR < 0.01. Among these loci, 20 are novel for SCZ, and four are novel for BD. Most
SCZ risk alleles (61 of 75, 81%) were associated with poorer cognitive performance, whereas most BD risk alleles (9 of 12,
75%) were associated with better cognitive performance. A gene set analysis of the loci shared between SCZ and intelligence
implicated biological processes related to neurodevelopment, synaptic integrity, and neurotransmission; the same analysis
for BD was underpowered. Altogether, the study demonstrates that both SCZ and BD share genetic influences with
intelligence, albeit in a different manner, providing new insights into their genetic architectures.
Introduction
Schizophrenia (SCZ) and bipolar disorder (BD) are severe
psychiatric disorders recognized as leading causes of mor-
bidity and mortality in the world [1, 2]. SCZ and BD share
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many clinical features [3], including disturbances in mood,
thought, perception, and social functioning, and they are often
accompanied by cognitive impairment [4, 5]. The cognitive
deficits are consistently found to be more severe in SCZ than
BD [6–8]. A wide range of cognitive domains are affected in
both SCZ [6, 7, 9, 10] and BD [6, 7, 11–14], including
executive function, verbal learning, processing speed, and
memory, as well as general intelligence. The general factor of
intelligence, denoted as g, is a latent trait that captures around
40–50% of the shared variance across diverse cognitive
abilities [15, 16]. It is noteworthy, however, that cognitive
dysfunction is not a prerequisite of either SCZ or BD, at least
in terms of traditional definitions of cognitive dysfunction [8].
Many individuals with SCZ and BD perform within the
normal range of cognitive functioning [6, 9, 17], and superior
intelligence occurs among individuals with both disorders,
although more frequently in BD [18–20]. Furthermore, both
higher and lower premorbid cognitive performance have been
linked to increased BD risk [20–22]. In SCZ, however, cog-
nitive underperformance often precedes the onset of psychotic
symptoms and subsequent diagnosis of SCZ by many years
[8, 23, 24]. Accumulating evidence indicates that intelligence
is a major determinant for many socioeconomic and health-
related outcomes in the general population [25, 26]. In addi-
tion, the degree of cognitive underperformance is a key pre-
dictor of functional and treatment outcome in both SCZ [6,
27] and BD [6, 28, 29]. Despite this, there are currently no
psychiatric treatments available that effectively amend cog-
nitive impairment [4, 5], and the limited mechanistic under-
standing prevents the development of novel effective
therapies.
SCZ, BD, and intelligence are complex, heterogeneous
phenotypes under strong genetic control, with heritability
estimates ranging between 0.6 and 0.8 for SCZ and BD [30],
and ~ 0.5 for cognitive abilities [31]. There is abundant
genetic overlap between SCZ and BD [32], in accordance
with their high degree of clinical overlap [3]. Results from
family and twin studies indicate that genetic liabilities of SCZ
and cognitive abilities covary [33–35], and molecular genetic
studies have implicated rare and common alleles influencing
both SCZ and cognitive abilites [36, 37]. Family studies have
found that cognitive impairments are more common among
unaffected relatives of patients with BD than in healthy con-
trols [13, 38–40], suggesting that genetic susceptibility to BD
may also contribute to cognitive dysfunction. Yet, whereas
genome-wide association studies (GWAS) analyses have
consistently found significant negative genome-wide correla-
tions between SCZ and cognitive abilities (rg ranging between
−0.2 and −0.4) [41–48], most studies have found no genome-
wide correlations between BD and cognitive abilites [41–49].
One study did find a significant genome-wide correlation
between BD and a measure of memory [41], but the latter
shows low test-retest correlation [50], low single nucleotide
polymorphism (SNP)-heritability (h2SNP = 0.05) [51], and no
genetic correlation with educational attainment [41], suggest-
ing that its genetic architecture may be different from that of
other cognitive traits.
Here we aimed to provide further insights into the
genetic relationship between SCZ, BD, and intelligence by
analyzing summary data from recent large GWAS on SCZ
(n= 82,315) [52], BD (n= 51,710) [49], and general
intelligence (n= 269,867) [44]. In these GWAS, 108
genomic loci were associated with SCZ at the genome-wide
significance level [52], 30 loci were associated with BD
[49], and 205 loci were associated with intelligence [44].
Among the loci, 24 were jointly associated with SCZ [52]
and intelligence [44], with SCZ risk linked to poorer cog-
nitive performance at 18 loci. There was a significant
moderate negative genetic correlation between SCZ and
intelligence (rg=−0.21, p= 3.82 × 10−17) [44]. Four
genome-wide significant loci were jointly associated with
BD [49] and intelligence [44], with BD risk linked to poorer
cognitive performance at three loci. In line with prior stu-
dies [41–48], the genetic correlation between BD and
intelligence was non-significant (rg=−0.05, p= 0.08)
[49]. Despite the success of these GWAS to uncover trait-
associated variants, large fractions of the polygenic archi-
tectures underlying SCZ, BD, and intelligence still remain
to be uncovered [44, 49, 52]. To identify additional com-
mon genetic variants jointly influencing these phenotypes,
we applied a conditional false discovery rate (condFDR)
approach [53, 54]. This method builds on an empirical
Bayesian statistical framework, and combines GWAS
summary data to increase statistical power to detect SNPs
that did not reach genome-wide significance [53, 54]. The
condFDR approach does not require a genetic correlation to
improve discovery, but leverages systematic co-localization
of SNP associations to prioritize likely pleiotropic SNPs
[55]. To our knowledge, there are no previous conditional
GWAS studies comparing BD and intelligence, whereas a
recent condFDR study identified 21 genomic loci shared
between SCZ and different cognitive abilities, where most
(18 out of 21) SCZ risk alleles were associated with poorer
cognitive performance [36]. Applying the same statistical
approach to larger GWAS samples [44, 49, 52], we here




We obtained GWAS results in the form of summary sta-
tistics (p values and z-scores) [44, 49, 52]. Data on SCZ and
BD were acquired from the Psychiatric Genomics
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Consortium. The SCZ data set consisted of 49 case–control
samples (34,241 cases with SCZ or schizoaffective disorder
and 45,604 controls) and three family-based association
studies (1235 parent-affected offspring trios) [52]. The BD
data set consisted of 20,352 cases and 31,358 controls from
32 cohorts [49]. Among the cases, 14,879 individuals had a
diagnosis of BD type I (BD1), 3421 had BD type II (BD2),
977 had schizoaffective disorder, bipolar type (SAB), and
the remaining unspecified BD [49]. Data on general intel-
ligence were based on 269,867 individuals drawn from 14
cohorts, primarily consisting of data from the UK Biobank
(n= 195,653) [44]. The cohorts contributing to the intelli-
gence GWAS either calculated Spearman’s g or used a
primary measure of fluid intelligence that correlates highly
with g [44, 56]. All GWAS investigated in the present study
were approved by the local ethics committees, and informed
consent was obtained from all participants. The Norwegian
Institutional Review Board for the South-East Norway
Region has evaluated the current protocol and found that no
additional institutional review board approval was needed
because no individual data were used. For details, see
Supplementary Methods and the original publications
[44, 49, 52].
Statistical analysis
To provide a visual pattern of overlap in SNP associations,
we constructed conditional quantile-quantile (Q-Q) plots.
The conditional Q-Q plots compare the association with a
primary trait across all SNPs and within SNPs strata
determined by their association with the secondary trait.
Pleiotropic enrichment exists if the proportion of SNPs
associated with a phenotype increases as a function of the
strength of the association with a secondary phenotype. In
conditional Q-Q plots, this enrichment is visualized as
successive leftward deflections from the null distribution,
and can be directly interpreted in terms of the true discovery
rate (1−FDR) [53–55]. To improve the discovery of genetic
variants associated with SCZ, BD, and intelligence, we
applied a condFDR statistical framework [53–55]. The
condFDR is an extension of the standard FDR, that re-ranks
the test-statistics of a primary phenotype based on a con-
ditional variable, in this case the strength of the association
with a secondary phenotype [53–55]. Inverting the roles of
primary and secondary phenotypes provides the inverse
condFDR value. The conjunctional FDR (conjFDR),
defined in turn as the maximum of the two condFDR values,
provides a conservative estimate of the FDR for association
with both phenotypes. P values were corrected for inflation
using a genomic inflation control procedure [53]. All code
used for carrying out the described analyses is available
upon request from the corresponding author. All analysis
was performed after excluding SNPs in the major extended
histocompatibility complex and 8p23.1 regions. For details,
see Supplementary Methods.
Genomic loci definition
We defined independent genomic loci according to the
FUMA [57] protocol. FUMA is an online platform for
functional mapping of genetic variants (http://fuma.ctglab.nl/)
[57]. First, we identified independent significant SNPs as
SNPs with condFDR < 0.01 and independent from each
other at r2 < 0.6. A subset of these in approximate linkage
equilibrium with each other at r2 < 0.1 were then selected as
lead SNPs. To define distinct genomic loci, we merged any
physically overlapping lead SNPs (LD blocks <250 kb
apart). The borders of the genomic loci were defined by
identifying all SNPs in LD (r2≧ 0.6) with one of the
independent significant SNPs in the locus. The region
containing all of these candidate SNPs was considered to be
a single independent genomic locus. All LD information
was calculated from the 1000 Genomes Project reference
panel [58]. We evaluated the directional effects of the loci
shared between SCZ, BD, and intelligence by comparing
their z-scores and odds ratios.
Functional annotation
Using FUMA [57], we functionally annotated all candi-
date SNPs in the genomic loci with a condFDR or
conjFDR value < 0.10 having an LD r2 ≧ 0.6 with one of
the independent significant SNPs. SNPs were annotated
with Combined Annotation Dependent Depletion
(CADD) [59] scores, which predict how deleterious the
SNP effect is on protein structure/function, RegulomeDB
[60] scores, which predict likelihood of regulatory func-
tionality, and chromatin states, which predict transcrip-
tion/regulatory effects from chromatin states at the SNP
locus [61, 62]. We also identified previously reported
GWAS associations in the NHGRI-EBI catalog [63]
overlapping with the identified loci. Moreover, we used
FUMA [57] to evaluate gene ontology (GO) [64] gene-set
enrichment for the genes nearest the identified shared loci.
Finally, we used data from the genotype tissue expression
(GTEx) resource [65], to determine gene expression and
assess expression quantitative trait locus (eQTL) func-
tionality of likely regulatory lead SNPs. All analyses were
corrected for multiple comparisons. For details, see Sup-
plementary Methods.
Results
We observed successive increments of SNP enrichment for
SCZ and BD as a function of the significance of the
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associations with intelligence (Fig. 1). This indicates poly-
genic overlap between the phenotypes. The reverse condi-
tional Q-Q plots demonstrate consistent enrichment in
intelligence given associations with SCZ and BD (Supple-
mentary Figure 1). To increase statistical power, we lever-
aged this pleiotropic enrichment using condFDR analysis
and re-ranked SCZ and BD SNPs conditional on their
association with intelligence, and vice versa. At condFDR
< 0.01, we identified 236 loci associated with SCZ and 48
loci associated with BD conditional on their association
with intelligence (Supplementary Tables 1–2). Next, we
identified 337 loci associated with intelligence conditional
on SCZ and 283 loci conditional on BD at condFDR < 0.01
(Supplementary Tables 3–4). Altogether, we identified 138
SCZ loci, 31 BD loci, and 165 intelligence loci that were
not identified in the original GWAS [44, 49, 52], demon-
strating the improved power for SNP discovery gained by
combining GWAS in a condFDR framework.
A total of 75 distinct genomic loci were jointly asso-
ciated with SCZ and intelligence at conjFDR < 0.01
(Fig. 2a; Supplementary Table 5). Forty-two of these loci
were not identified in the original SCZ GWAS [52].
Twenty-two of the 42 were however reported in other SCZ
GWAS according to the NHGRI-EBI catalog (Supplemen-
tary Table 6), yielding a total number of 20 novel SCZ risk
loci among the shared loci [63]. Further, 37 of the top lead
SNPs in these loci were associated with BD at p < 0.05. As
denoted by the sign of the effect sizes, most of the SCZ risk
alleles (61 out of 75; Supplementary Table 5) were asso-
ciated with cognitive underperformance, corroborating prior
findings [36]. We also identified 12 distinct loci shared
between BD and intelligence at conjFDR < 0.01 (Fig. 3a;
Supplementary Table 7). Eight of these were not identified
in the original BD GWAS [49]. Four of the eight had
however been identified in prior BD GWAS (Supplemen-
tary Table 8), yielding a total of four novel BD risk loci
among the shared loci [63]. Eight of the lead SNPs in these
loci were associated with SCZ at p < 0.05. Although SNPs
near SRPK2 on chromosome 7 reached genome-wide sig-
nificance in both GWAS on BD [49] and intelligence [44],
no SNPs in this locus were jointly associated with these
phenotypes at conjFDR < 0.01 but rs9655780 came close
(conjFDR= 0.012; Supplementary Table 9). At the shared
loci, 9 out of 12 BD risk alleles were associated with higher
cognitive performance (Supplementary Table 7). However,
among the shared loci at conjFDR < 0.05, only 40 out of 79
(51%) loci had concordant effects on BD risk and intelli-
gence (Supplementary Table 9). To visualize the distribu-
tion of the shared variants, we constructed “conjFDR
Manhattan plots” where all SNPs without pruning are
shown, and the independent significant lead SNPs are
encircled in black (Figs. 2a, 3a).
Functional annotation [57] of all SNPs having a
conjFDR value < 0.10 in the loci shared between SCZ and
intelligence (n= 6853; Fig. 2b–d) demonstrated that these
were mostly intronic and intergenic, whereas 2.0% were
exonic (Supplementary Table 10). Of the 75 top lead SNPs
in the loci shared between SCZ and intelligence, 40 were
located inside a protein-coding gene and 11 inside a non-
coding RNA (Supplementary Table 5). Of the 75 top lead
SNPs, two SNPs (rs11695125, rs1805645) had CADD
scores above 12.37, the threshold suggested to signify
deleteriousness [59], and one SNP (rs5751191) had a
RegulomeDB [60] score of 1f, suggesting that it was likely
affecting binding sites (Supplementary Table 5). We fol-
lowed up this finding using the GTEx database [65], and
found that rs5751191 was significantly associated with
eQTL functionality in different brain regions for genes
CYP2D6, NAGA, WBP2NL, and RP4-669P10.16 (Supple-
mentary Table 11). Using GTEx [65] data, we found that
the genes nearest the 75 shared loci were significantly
overexpressed in multiple brain regions (Supplementary
Fig. 1 Polygenic overlap between schizophrenia (SCZ), bipolar dis-
order (BD), and intelligence. Conditional Q-Q plots of nominal versus
empirical −log10p values (corrected for inflation) in a SCZ and b BD
below the standard GWAS threshold of p < 5 × 10−8 as a function of
significance of association with intelligence, at the level of p⩽0.1, p ⩽
0.01, p ⩽ 0.001, respectively. The blue lines indicate all SNPs. The
dashed lines indicate the null hypothesis
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Figures 2–3). GO gene-set analysis for these genes revealed
32 significantly associated biological processes, the most
strongly associated being “regulation of neuron differ-
entiation”, “regulation of cell development”, “neurogen-
esis”, “modulation of synaptic transmission”, and
“regulation of receptor binding” (Supplementary Table 12).
Further, the genes were significantly associated with 10
cellular component gene sets, including “neuronal projec-
tion”, “the synapse”, and “the anchored part of mem-
branes”, as well as six molecular function gene sets, the
most strongly associated being “GABA receptor binding”
(Supplementary Table 12).
We also functionally annotated all SNPs having a
conjFDR value < 0.10 in the loci shared between BD and
Fig. 2 a Common genetic variants jointly associated with schizo-
phrenia (n= 82,315) and intelligence (n= 269,867) at conjunctional
false discovery rate (conjFDR) < 0.01. Manhattan plot showing the –
log10 transformed conjFDR values for each SNP on the y axis and
chromosomal positions along the x axis. The dotted horizontal line
represents the threshold for significant shared associations (conjFDR <
0.01, ie., −log10(conjFDR) > 2.0). Independent lead SNPs are encir-
cled in black. The significant shared signal in the major histo-
compatibility complex region (chr6:25119106–33854733) is
represented by one independent lead SNP. Further details are provided
in Supplementary Table 5. b Distribution of functional consequences
of SNPs in the shared genomic risk loci. c Distribution of Reg-
ulomeDB score for SNPs in shared genomic loci, with a low score
indicating a higher likelihood of having a regulatory function. d The
minimum chromatin state across 127 tissue and cell types for SNPs in
shared genomic loci, with lower states indicating higher accessibility
and states 1–7, referring to open chromatin states
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intelligence (n= 846; Fig. 3b–d). 4.6% were exonic and
most of the others were intronic or intergenic (Supple-
mentary Table 13). Of the 12 top lead SNPs in the loci
shared between BD and intelligence, seven were located
inside a protein-coding gene and one inside a non-coding
RNA (Supplementary Table 7). One of the top SNPs
(rs60144015; intronic variant within FOXO6) had a CADD
score of 18.65, suggesting deleteriousness (Supplementary
Table 7). The genes nearest the 12 shared loci were
significantly overexpressed in three tissues, all in the brain,
namely “frontal cerebral cortex BA9”, “nucleus accum-
bens” and “cerebral cortex” (Supplementary Figures 2
and 4). Gene-set analysis identified one biological process
significantly associated with these genes: “long-chain fatty
acid metabolic process” (Bonferroni-corrected p value
0.015; data not shown). No gene sets for cellular compo-
nents or molecular functions were significantly associated
with these genes.
Fig. 3 a Common genetic variants jointly associated with bipolar
disorder (n= 51,710) and intelligence (n= 269,867) at conjunctional
false discovery rate (conjFDR) < 0.01. Manhattan plot showing the –
log10 transformed conjFDR values for each SNP on the y axis and
chromosomal positions along the x axis. The dotted horizontal line
represents the threshold for significant shared associations (conjFDR <
0.01, ie, –log10 (conjFDR) > 2.0). Independent lead SNPs are encircled
in black. Further details are provided in Supplementary Table 7.
b Distribution of functional consequences of SNPs in the shared
genomic risk loci. c Distribution of RegulomeDB score for SNPs in
shared genomic loci, with a low score indicating a higher likelihood of
having a regulatory function. d The minimum chromatin state across
127 tissue and cell types for SNPs in shared genomic loci, with lower
states indicating higher accessibility and states 1–7 referring to open
chromatin states
O. B. Smeland et al.
Discussion
In the current study, we analyzed large GWAS datasets on
SCZ, BD, and intelligence [44, 49, 52] to gain insights into
their shared genetic basis. First, we showed that common
genetic variants associated with SCZ and BD are enriched
for associations with intelligence (Fig. 1). Using conjFDR
analysis we leveraged this pleiotropic enrichment and
identified 75 genomic loci jointly associated with SCZ and
intelligence (Fig. 2a) and 12 genomic loci jointly associated
with BD and intelligence (Fig. 3a). Among the shared loci,
20 are novel SCZ risk loci and four are novel BD risk loci.
Altogether, this study indicates that large fractions of the
genomic risk architectures underlying SCZ and BD also
influence intelligence, albeit in a different manner.
This provides new insights into the molecular genetic
underpinnings of the altered cognitive performance in these
patients groups [6–14, 38]. Further experimental inter-
rogation of the identified loci may uncover biological
insights that can inform the development of novel effective
cognitive treatments, which remains to this day a pressing
need in psychiatry [4, 8].
The GWAS power for BD (n= 51,710) [49] is still
trailing that of SCZ (n= 82,315) [52], which limits the
validity of comparing the present findings for the two dis-
orders. Yet, the study strengthens prior genetic evidence
[44, 49] that SCZ and BD differ in their relation to intelli-
gence [8]. Whereas most identified SCZ risk alleles (81%)
were associated with lower cognitive performance (Sup-
plementary Table 5), most BD risk alleles (75%) were
associated with better cognitive performance (Supplemen-
tary Table 7). The discrepant results may thus highlight
unique genetic effects underlying SCZ and BD, contrasting
their otherwise high degree of genetic overlap [32]. Yet, 8
of 12 lead SNPs associated with both BD and intelligence
were also associated with SCZ at p < 0.05, and 37 of 75 lead
SNPs associated with both SCZ and intelligence were also
associated with BD at p < 0.05. At first, these results suggest
that many of the genetic variants do not exclusively influ-
ence SCZ or BD, although they may be more specific to one
of the disorders. Second, the consistent effects between the
disorders support the validity of the present findings, even
though the genetic correlation between BD and SCZ is not
perfect (rg= 0.70 [49]).
To our knowledge, the finding of polygenic overlap
between BD and intelligence is novel (Fig. 1b, Fig. 3a).
Prior investigations did not find any genetic correlation
between BD and cognitive abilities using LD score
regression and polygenic risk scores [41–49]. However,
these methods are unable to detect genetic overlap if there
are no consistent effect directions among the overlapping
SNPs [66, 67]. Indeed, at the 79 loci associated with both
BD and intelligence at a lower significance threshold
(conjFDR < 0.05, Supplementary Table 9), only 51% of BD
risk alleles were associated with higher cognitive perfor-
mance. This balanced mixture of directional effects com-
plies with the non-significant genetic correlation between
the phenotypes [44, 49], and indicates that a substantial
polygenic component underlying BD risk also influences
intelligence. The converging genetic data do not provide an
explanation for the cognitive impairments associated with
BD [6, 7, 11–14, 38], suggesting that environmental factors
or undetected rare and common genetic variants may also
play a role. Our study further dissects the well-established
polygenic overlap between SCZ and cognitive abilities [36,
41–47], strengthening the hypothesis that common genetic
variance may contribute to cognitive dysfunction in SCZ. It
is nevertheless noteworthy that SCZ risk alleles were
associated with higher cognitive performance at almost one-
fifth (~19%) of the shared loci. Overall, our findings suggest
that the genetic relationship between SCZ, BD, and intel-
ligence is more complex than what is expressed by their
genetic correlations [44, 49], which may help explain the
diverse cognitive performance within these patient groups
[6, 9, 17–22].
Phenotypic refinement [32] may further illuminate the
genetic relationship between BD, SCZ, and intelligence. For
example, patients with BD without a history of psychosis
showed milder cognitive deficits than those with a history of
psychosis [7], whereas BD1 is associated with more severe
cognitive deficits than BD2 [14]. In the BD GWAS pre-
sently analyzed, 73% of cases had BD1, 17% of cases had
BD2, and 5% of cases had SAB [49]. However, larger
GWAS samples are required to clarify any genetic differ-
ences underlying these subtypes. Note that the genetic
effects on intelligence were determined in individuals
representative of the normal population [44]. Hence, the
experimental design of the conjFDR approach ensures that
the cognitive effects here linked to BD and SCZ risk alleles
are not attributable to confounding known to bias neu-
ropsychological assessment of these patient groups, such as
high symptomatic load or medication [68]. Although some
participants in the intelligence GWAS [44] likely suffered
from psychiatric disorders, their contribution would not bias
the results as they represent a minor fraction of the total
GWAS sample [44].
The genes nearest the 75 loci shared between SCZ and
intelligence and the 12 loci shared between BD and intelli-
gence were significantly overexpressed in human brain
regions (Supplementary Figures 2–4). Although these genes
are not necessarily the genes by which the genetic variants
exert their phenotypic effect, the findings support the
importance of brain-expressed genes in the shared genetic
etiology underlying SCZ, BD, and intelligence. The gene-set
enrichment analysis implicated 32 biological processes sig-
nificantly associated with the loci shared between SCZ and
Genome-wide analysis reveals extensive genetic overlap between schizophrenia, bipolar disorder, and. . .
intelligence, converging on processes related to neurodeve-
lopment, synaptic integrity, and neurotransmission (Sup-
plementary Table 10). These processes are previously linked
to SCZ risk [5, 37, 69] and intelligence [44, 56]. In line with
these results, the gene-set analysis for cellular components
revealed significant associations for neuronal projections, the
synapse, and the anchored part of membranes, among others
(Supplementary Table 12). The most strongly associated
gene-set for molecular functions was “GABA receptor
binding”, suggesting that inhibitory signaling may be
affected. Intriguingly, we identified several loci shared
between SCZ and intelligence previously associated with
subcortical brain volumes (at DPP4, SPATS2L, NEK4,
FOXO3, and DCC) [70, 71], providing plausible genetic
links between SCZ, intelligence and brain structure forma-
tion. At all of these loci, SCZ risk was associated with
poorer cognitive performance. We identified four loci shared
between BD and intelligence that had not reached genome-
wide significance in the BD GWAS [49] presently analyzed
but were identified in prior BD GWAS (at SUMO2P2 [72],
TENM4/ODZ4 [73, 74], RHEBL1 [72, 73], and NFIX [73];
Supplementary Table 8), supporting their role in BD risk.
Experimental follow-up studies are needed to determine the
causal variants underlying the shared associations detected
here, and to detail how these variants individually and col-
lectively affect brain function and development.
In conclusion, our study demonstrates polygenic overlap
between intelligence and the psychiatric disorders SCZ and
BD, providing new insights into their common genetic
basis. Owing to the well-powered GWAS [44, 49, 52]
investigated and their large degree of overlapping associa-
tions, the number of shared loci identified here substantially
exceeds that of prior condFDR studies [36, 53, 54, 70]. Yet,
the strong pleiotropic enrichment observed suggests that
many more loci shared between SCZ, BD, and intelligence
will be identified as GWAS samples get larger. This may
have profound implications for understanding, and poten-
tially treating, the cognitive abnormalities associated with
these psychiatric disorders.
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